Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity

Prostate

Volumn 70, Issue 7, 2010, Pages 745-754

  Kawata, Hiromitsu ^a   Ishikura, Nobuyuki ^a   Watanabe, Miho ^a   Nishimoto, Ayako ^a   Tsunenari, Toshiaki ^a   Aoki, Yuko ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Anti androgen; Hormone refractory; LNCaP; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; METRIBOLONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; GENE AMPLIFICATION; GENE MUTATION; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DIHYDROTESTOSTERONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; MALE; MICE; NITRILES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; RECEPTORS, ANDROGEN; TESTOSTERONE; TIME FACTORS; TOSYL COMPOUNDS;

EID: 77951786995     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21107     Document Type: Article

References (42)

1. Bosetti C, Bertuccio P, Levi F, Lucchini F, Negri E, La Vecchia C. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol 2008;19(4):631-640.
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2002: Based on data from 11 population-based cancer registries. Jpn J Clin Oncol 2008;38(9):641-648.
3. Qiu D, Katanoda K, Marugame T, Sobue T. A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958-2004). Int J Cancer 2009;124(2):443-448.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96.
5. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 2000;31(5):578-583. (Pubitemid 30323983)
6. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34(7):646-653. (Pubitemid 36875509)
7. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004;64(24):9209-9216. (Pubitemid 39665537)
8. Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y. Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009;115(15):3437-3445.
9. Arai Y, Akaza H, Deguchi T, Fujisawa M, Hayashi M, Hirao Y, Kanetake H, Naito S, Namiki M, Tachibana M, Usami M, Ohashi Y. Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: A multicenter, randomized, double-blind, comparative study. J Cancer Res Clin Oncol 2008;134(12):1385-1396.
10. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003;91(5):455-461. (Pubitemid 36359626)
11. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP. Bicalutamide 150mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97(2):247-254.
12. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: Locking up the molecular escape routes. Clin Cancer Res 2009;15(10):3251-3255.
13. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12(6):1665-1671.
14. Schroder FH. Progress in understanding androgen-independent prostate cancer (AIPC): A review of potential endocrinemediated mechanisms. Eur Urol 2008;53(6):1129-1137.
15. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994;54(6):1566-1573. (Pubitemid 24106424)
16. Gao M, Ossowski L, Ferrari AC. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their and rogenindependent derivative. J Cell Physiol 1999;179(3):336-346. (Pubitemid 29203158)
17. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999;81(2):242-251. (Pubitemid 29423702)
18. Joly-Pharaboz MO, Ruffion A, Roch A, Michel-Calemard L, Andre J, Chantepie J, Nicolas B, Panaye G. Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line. J Steroid Biochem Mol Biol 2000;73(5):237-249.
19. Lu S, Tsai SY, Tsai MJ. Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology 1999;140(11):5054-5059.
20. Tso CL, McBrideWH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 2000;6(4): 220-233.
21. Gustavsson H, Welen K, Damber JE. Transition of an androgendependent human prostate cancer cell line into an androgenindependent subline is associated with increased angiogenesis. Prostate 2005;62(4):364-373. (Pubitemid 40227488)
22. Lee SO, Dutt SS, Nadiminty N, Pinder E, Liao H, Gao AC. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line. Prostate 2007;67(12):1293-1300. (Pubitemid 47435777)
23. Iwasa Y, Mizokami A, Miwa S, Koshida K, Namiki M. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP. Int J Urol 2007;14(3):233-239. (Pubitemid 46423241)
24. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, MiyamotoM. Novel mutations of androgen receptor:Apossible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63(1):149-153.
25. Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA, Liao S. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate 2005;65(4):287-298. (Pubitemid 41759960)
26. Hobisch A, Fritzer A, Comuzzi B, Fiechtl M, Malinowska K, Steiner H, Bartsch G, Culig Z. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Prostate 2006;66(4):413-420. (Pubitemid 43346952)
27. Kashiwagi B, Shibata Y, Ono Y, Suzuki R, Honma S, Suzuki K. Changes in testosterone and dihydrotestosterone levels in male rat accessory sex organs, serum, and seminal fluid after castration: Establishment of a new highly sensitive simultaneous androgen measurement method. J Androl 2005;26(5):586-591. (Pubitemid 41161318)
28. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, Nakagawa H. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008;99(1):81-86. (Pubitemid 350239034)
29. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57(3):205-225. (Pubitemid 37267805)
30. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-39. (Pubitemid 38524696)
31. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89(3):552-556. (Pubitemid 37026442)
32. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.AmJ Pathol 2004;164(1):217-227.
33. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997;57(2):314-319. (Pubitemid 27036612)
34. Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, Vidaud M. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001;61(5):1919-1926. (Pubitemid 32692008)
35. Linja MJ, Savinainen KJ, Saramaki OR,TammelaTL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61(9):3550-3555. (Pubitemid 32694958)
36. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9(4):401-406.
37. Lin HK,HuYC, Yang L, Altuwaijri S, Chen YT, Kang HY, Chang C. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 2003;278(51):50902-50907. (Pubitemid 38020321)
38. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgeninduced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001;98(13):7200-7205. (Pubitemid 32567926)
39. McCall P, Gemmell LK, Mukherjee R, Bartlett JM, Edwards J. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br J Cancer 2008;98(6):1094-1101. (Pubitemid 351399795)
40. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-790.
41. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26(28):4563-4571.
42. O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90(12):2317-2325.